YieldMax MSTR Option Income Strategy ETF vs Neurocrine Biosciences Inc — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $13.55, while Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MSTY | NBIX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $108.80 | $180.55 |
52-Week Low | $11.55 | $123.10 |
Market Cap | — | $17.40B |
Enterprise Value | — | $16.49B |
Trailing returns across standard periods
Latest headlines on both assets
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →